The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Dr. Reddy’s Laboratories (“Dr. Reddy’s” or the “Company”) (NYSE: RDY) investors concerning...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2...
Investigation focuses on RDY losses after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches and shares fell approximately 9%.
The investigation focuses on RDY investor losses tied to Dr. Reddy’s FY27 margin guidance after the Company disclosed a ₹2.4 billion provision connected to out-of-spec semaglutide batches.
RDY investor losses followed a sharp split between adjusted profit figures and reported results. The investigation focuses on whether Dr. Reddy's presentation of adjusted metrics left investors exposed...
RDY shares fell approximately 9% after Q1 FY27 results showed a 5.66% year-over-year revenue decline and a 68.7% profit decline. The investigation focuses on investor losses tied to the market reaction...
Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets...
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28 th , 2026, marking the company’s readiness to serve Canadian patients...
Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide...